MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ixekizumab

CAS No. : 1143503-69-8

MCE 站：Ixekizumab

产品活性：Ixekizumab 是一种人源化 IgG4 单克隆抗体，可选择性结合和中和白细胞介素 IL-17A (K_D<3 pM)。Ixekizumab 直接阻断 IL-17A 与 IL-17RA 的结合，但不与其他 IL-17 家族成员结合。Ixekizumab 用于中重度斑块型银屑病的研究。

研究领域：Immunology/Inflammation

作用靶点：Interleukin Related

In Vitro: The equilibrium K_D of Ixekizumab for human and cynomolgus monkey IL-17A were 1.8 pM and 0.8 pM, respectively. Ixekizumab also bound to rabbit IL-17A, but the affinity was lower, and the binding was heterogeneous (K_D of 1.3 nM and 14 nM). Ixekizumab shows no binding to either mouse or rat IL-17A.
Ixekizumab (0.1-10000 pM) inhibits human IL-17A- or human IL-17A/F heterodimer-induced growth-regulated oncogene (GRO)α secretion from HT-29 cells in a dose-dependent fashion. Ixekizumab inhibits cynomolgus monkey IL-17A-induced GROα secretion from HT-29 cells in a dose-dependent fashion.

In Vivo: Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner.
In male cynomolgus monkeys, following IV administration of 1 mg/kg, Ixekizumab is eliminated with a mean half-life of 6.5 days. After SC administration of 1 mg/kg, Ixekizumab reaches an average maximal plasma concentration of 11.1 ?g/mL ~72 hours postdose. The mean elimination half-life following the SC injection was 10.3 days.

相关产品：Resatorvid  |  Disulfiram  |  Tocilizumab  |  Diacerein  |  Vidofludimus  |  LMT-28  |  Muscone  |  SC144  |  Hydrocortisone hemisuccinate  |  RCGD423  |  Neochlorogenic acid  |  Y-320  |  Ginsenoside Rh1  |  Semapimod tetrahydrochloride  |  Pectolinarin  |  Ginsenoside Rc  |  Mulberroside A  |  Madecassic acid  |  Methylthiouracil  |  Balsalazide  |  Kaempferol 3-O-β-D-glucuronide  |  Reslizumab  |  Suplatast (Tosilate)  |  YQ128  |  Ginsenoside F3  |  Tyrphostin A1  |  Dexanabinol  |  Eucalyptol  |  NFAT Transcription Factor Regulator-1

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。